Projektnummer

0069404

Zusammenfassung

SARS-CoV-2 and many other viruses acquire genetic mutations and undergo genome recombination events to adapt to a hostile environment. Modern therapies respond to this challenge by simultaneously targeting multiple key proteins involved in virus replication. The consortium envisions the next generation of drugs against SARS-CoV-2 to be programmable and sequence-specific. Recently, Cas13-nucleases have been added to the evolving CRISPR-toolbox, which target and efficiently cleave RNA molecules. Upon Cas13-mediated cleavage, the viral RNA will undergo rapid degradation by exonucleases in...